No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish pharmaceutical company has enacted a hiring freeze—the latest sign of a sinking financial outlook for the once-titan of the obesity treatment world.

A rumor that pharmaceutical companies behind popular weight-loss and diabetes medications like Ozempic faced lawsuits totaling more than $2 billion circulated online in August 2025.  Claims of lawsuits against Ozempic and similar drugs are indeed true.

According to a report by the Financial Times, Morgan & Morgan, a law firm, revealed it had filed a case on behalf of a 44-year-old woman from Louisiana who suffered severe vomiting after taking Ozempic and Mounjaro.

The pharma giant has almost doubled the size of its workforce over the last five years but is now looking to tighten cost controls amid challenges in the obesity-drug market.

“Semaglutide has been in the US for more than eight years now. In India also, the oral version of this molecule is there for more than 3 years. It is one of the most well studied compounds”, says Dr Shashank R Joshi, a Mumbai based endocrinologist and medical researcher.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.

Data to highlight the impact of Wegovy® (semaglutide 2.4 mg) on atrial fibrillation – a common heart rhythm condition – in people living with obesity (SELECT study)Additional Rybelsus® and Ozempic® da

The legal battle over Ozempic is getting bigger by the day. Multiple lawsuits have been filed against the diabetes-medicine-turned weight-loss drug. What started as scattered complaints has grown into more than a thousand lawsuits against Novo Nordisk.